R3TA
Triple incretin-family receptor agonist studied in vitro.
Specification
- Catalogue ID: VL-011
- Listed purity specification: 99.8%
- Formulation: Lyophilized
- Quantity: 20mg / Vial
- Price: £228.00
Triple receptor agonist · GIP/GLP-1/glucagon receptor binding research
R3TA (LY3437943) is a synthetic peptide triple agonist with affinity for the GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR). It is an unlicensed research compound currently under Phase III clinical investigation.
In receptor-binding and cell-signalling assays, r3ta engages all three receptors through Gαs-coupled cAMP signalling pathways. Its triple-receptor profile is studied in vitro to characterise the relative contribution of each receptor to downstream metabolic signalling outcomes.
No physiological or therapeutic properties are claimed; supplied strictly as a research reagent for in-vitro laboratory use only. Offered solely as an unlicensed research compound.
Compound identity
- Molecular formula: C₂₅₇H₄₀₀N₆₀O₈₀S₂
- Molecular weight: 5765.47 Da
- Solubility: Soluble in aqueous solution at physiological pH
- Solution preparation: No fixed volume: solvent and concentration depend on the sequence and the assay (see published solubility data); swirl gently
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.